tMQ
Total Test = +332%
Free Test = +370%
LH Raises = +252%
Estradiol = -47%
Letrozole once a week normalizes serum testosterone in obesity-related male hypogonadism
Abstract
Objective: Isolated hypogonadotropic hypogonadism (IHH) is frequently observed in severely obese men, probably as a result of increased estradiol (E2) production and E2-mediated negative feedback on pituitary LH secretion. Aromatase inhibitors can reverse this process. This study evaluates whether letrozole once a week can normalize serum testosterone in severely obese men and maintain its long term effect.
Design: Open, uncontrolled 6-month pilot study in 12 severely obese men (body mass index 35.0 kg/m2) with obesity-related IHH and free testosterone levels !225 pmol/l, treated with 2.5 mg letrozole once a week for 6 months.
Results: Six weeks of treatment reduced total E2 from 123G11 to 58G7 pmol/l (P!0.001, meanGS.E.M.), and increased serum LH from 4.4G0.6 to 11.1G1.5 U/l (P!0.001). Total testosterone rose from 5.9G0.5 to 19.6G1.4 nmol/l (P!0.001), and free testosterone from 163G13 to 604G 50 pmol/l (P!0.001). Total testosterone rose to within the normal range in all subjects, whereas free testosterone rose to supraphysiological levels in 7 out of 12 men. The testosterone and E2 levels were stable throughout the week and during the 6-month treatment period.
Conclusion: Letrozole 2.5 mg once a week produced a sustained normalization of serum total testosterone in obese men with IHH. However, free testosterone frequently rose to supraphysiological levels. Therefore, a starting dose <2.5 mg once a week is recommended.
http://www.ncbi.nlm.nih.gov/pubmed/18426834
Free Test = +370%
LH Raises = +252%
Estradiol = -47%
Letrozole once a week normalizes serum testosterone in obesity-related male hypogonadism
Abstract
Objective: Isolated hypogonadotropic hypogonadism (IHH) is frequently observed in severely obese men, probably as a result of increased estradiol (E2) production and E2-mediated negative feedback on pituitary LH secretion. Aromatase inhibitors can reverse this process. This study evaluates whether letrozole once a week can normalize serum testosterone in severely obese men and maintain its long term effect.
Design: Open, uncontrolled 6-month pilot study in 12 severely obese men (body mass index 35.0 kg/m2) with obesity-related IHH and free testosterone levels !225 pmol/l, treated with 2.5 mg letrozole once a week for 6 months.
Results: Six weeks of treatment reduced total E2 from 123G11 to 58G7 pmol/l (P!0.001, meanGS.E.M.), and increased serum LH from 4.4G0.6 to 11.1G1.5 U/l (P!0.001). Total testosterone rose from 5.9G0.5 to 19.6G1.4 nmol/l (P!0.001), and free testosterone from 163G13 to 604G 50 pmol/l (P!0.001). Total testosterone rose to within the normal range in all subjects, whereas free testosterone rose to supraphysiological levels in 7 out of 12 men. The testosterone and E2 levels were stable throughout the week and during the 6-month treatment period.
Conclusion: Letrozole 2.5 mg once a week produced a sustained normalization of serum total testosterone in obese men with IHH. However, free testosterone frequently rose to supraphysiological levels. Therefore, a starting dose <2.5 mg once a week is recommended.
http://www.ncbi.nlm.nih.gov/pubmed/18426834
Krzysztof Piekarz
MrPostman
wnc1964
jordanwlkp
game1988
flex1976
